An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study
An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@novonordisk.com(+1) 866-867-7178
Los Angeles, California 90027, United States
Los Angeles, California 90027, United States
Washington D.C., District of Columbia 20010, United States
Hollywood, Florida 33023, United States
Augusta, Georgia 30912, United States
New York, New York 10032, United States
Charlotte, North Carolina 28204, United States
Winston-Salem, North Carolina 27157, United States
Charleston, South Carolina 29425, United States
Toronto, Ontario M5G 2C4, Canada
Alsharkia, Egypt, 44519, Egypt
Berlin, 13353, Germany
Freiburg im Breisgau, 79106, Germany
Larissa, Thessaly 41221, Greece
Raipur, Chhattisgarh 492099, India
Gujarat, 395002, India
Maharashtra, 440012, India
Orbassano, Torino 10043, Italy
Siaya, Siaya County 40600, Kenya
Ituku-Ozalla, Enugu State 400001, Nigeria
Ibadan, Oyo State 0000, Nigeria
Mersin, 33110, Turkey (Türkiye)
Mersin, 33110, Turkey (Türkiye)